Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2012

View Archived Issues

U.S. and Australian group prepares new anticancer compounds

New anticancer agents synthesized

Common polymorphism linked to atherosclerosis

Australian study unveils new possible atherosclerosis marker in diabetes

Gene-modified cells are chemoprotective in phase I/II glioblastoma trial

Swiss company presents new neurotrypsin inhibitors

Merck KGaA divulges novel anticancer compounds

Novel serotonin 5-HT6 receptor ligands reported by Abbott

Novel FLAP inhibitors patented by Boehringer Ingelheim

Roche group identifies new cathepsin inhibitors

NIH awards grant to researchers developing new TB vaccine

Ongoing ASCO meeting features first clinical data on multikinase inhibitor

Cancer Research UK program aids trials of targeted cancer treatments

RaQualia begins first-in-human study of RQ-00000010

Mitsubishi Tanabe terminates license agreement

Cell Therapeutics completes acquisition of S*BIO product

CSL Behring submits application for Privigen

NicOx announces board's decision on remaining Altacor equity

Novartis ALK inhibitor for cancer shows promise in first-in-human trial

EpiCept receives EMA scientific advice for CIPN program

Auxilium planning sBLA for Xiaflex in new indication

Lilly launches radioactive diagnostic in select U.S. markets

Orexo and ProStrakan reconfigure worldwide rights to cancer pain product

Stiefel to acquire rights to investigational drug for psoriasis and atopic dermatitis

Forest Laboratories and Nabriva to collaborate on development of antibacterial agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...